Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
moroctocog alfa
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Moroctocog alfa is a second-generation recombinant B-domain deleted coagulation factor VIII (rFVIII) used for the treatment and prevention of bleeding episodes in patients with hemophilia A. Developed by Pfizer (following its acquisition of Wyeth), it is produced using a recombinant DNA technology in an albumin-free cell culture (AF-CC) system, which eliminates the use of human or animal-derived proteins during the manufacturing process to minimize the risk of pathogen transmission. The drug functions as a replacement therapy for the deficient or absent endogenous factor VIII. Once administered, it acts as a cofactor for activated factor IX in the intrinsic pathway of the coagulation cascade, facilitating the activation of factor X and leading to the formation of a stable fibrin clot. It is indicated for on-demand treatment, routine prophylaxis to reduce the frequency of bleeding episodes, and perioperative management in both adult and pediatric patients.
- Brand names
- XynthaReFactoXyntha SolofuseReFacto AF
- Other names
- recombinant coagulation factor VIIIBDDrFVIIIB-domain deleted recombinant factor VIIIantihemophilic factor (recombinant)moroctocog alfa (AF-CC)
02
Targets
Coagulation Factor IXa
Beyond the preview
Go deeper on moroctocog alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on moroctocog alfa.